Further Development and Assessment of Tools to Measure Risk Factors for and Treatment of Thiamine Deficiency Disorders

April 21, 2025 updated by: University of California, Davis

Further Development and Assessment of Tools to Measure Risk Factors for and Treatment of Thiamine Deficiency Disorders: a Comparison of Rural and Urban Contexts in Lao PDR

Thiamine deficiency, including the most severe form infantile beriberi, is a public health concern across South and Southeast Asia, where monotonous diets rely on thiamine-poor white rice. Food insecurity, food preparation and cooking practices, anti-thiamine compound consumption and culturally determined postpartum food restrictions precipitate thiamine deficiency in these high-risk regions. The risk of thiamine deficiency is highest in the first year of life, especially among exclusively or predominantly breastfed infants of mothers who are thiamine deficient themselves, as thiamine content of breastmilk is related to maternal thiamine status.

However, diagnosis of infantile thiamine deficiency is challenging due to the highly variable, non-specific clinical manifestations, referred to as thiamine deficiency disorders (TDD), that often overlap with other conditions, resulting in misdiagnosis and missed treatment opportunities, which can be fatal or have irreversible consequences. Considering that breastfed infants are at highest risk, a large proportion of infant deaths could be avoided if: 1) infants with TDD were immediately treated with thiamine when medically indicated and, importantly; 2) thiamine deficiency was prevented by improving thiamine status among breastfeeding women. The latter is important given emerging evidence of long-term neurocognitive deficits of severe and even subclinical thiamine deficiency.

In light of these diagnostic uncertainties, it was recognised that a case definition for thiamine responsive disorders (TRD) would help to better identify infants with TDD who would benefit from timely thiamine treatment. This study will test the usefulness of a recently developed case definition for TRD and practical tool in different contexts in Lao PDR where TDD have been reported. Secondly, data on diet, maternal and household risk factors for TDD in different contexts will be used to propose a community risk factor screening tool to better identify populations at risk of thiamine deficiency and help advocate for and guide planning of preventive programmes.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The study's primary objective is to determine the usefulness of a TRD case definition and practical tool in identifying infants and young children that would benefit from thiamine treatment in different contexts in Lao PDR, specifically urban Vientiane and rural Luang Prabang. Clinical observers based at the participating hospitals within each country/region will record the presenting signs and symptoms of all children within the target age range (21 days - <18 months) over a one month period. For children who meet the eligibility criteria and informed consent is obtained, information will be collected on duration of hospital stay, received medical treatments, final physician diagnosis and risk factor questionnaires (see below). This data will be used to determine the sensitivity and specificity of the practical TRD case definition tool to accurately identify children who would benefit from thiamine treatment and reduce treatment uncertainties

The secondary objective is to explore risk factors associated with TDD/TRD among infants and young children and their mothers. This will help to identify potential metrics that could be included in a community risk factor screening tool to identify population groups at risk of thiamine deficiency so appropriate preventive interventions can be implemented. Data will be collected on diet and household risk factors for thiamine deficiency, including infant and young child feeding practices, maternal dietary practices, maternal health status and household socioeconomic status and food security.

Study Type

Observational

Enrollment (Actual)

42

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Luang Prabang, Lao People's Democratic Republic
        • Lao Friends Hospital for Children
      • Vientiane, Lao People's Democratic Republic
        • Children's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 weeks to 1 year (Child)

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Infants and young children in the target age range (21 days - <18 months) who are admitted to the collaborating hospitals with at least one of the signs/symptoms suggestive of TDD will be eligible for participation.

Mothers of all participating children will be invited to participate in the study.

Description

Inclusion Criteria:

  • Infants and young children aged 21 days - <18 months presenting to the collaborating hospitals and presenting with at least one of the following signs and symptoms consistent with TDD:

    • Enlarged liver (liver edge >2 cm below the right costal margin)
    • Edema
    • Tachypnea (respiratory rate >60/min for 3-8 weeks; >50/min for 2-11 months; >40/min for 12-18 months)
    • Tachycardia (heart rate >160/min for <12 months; >120/min for 12-18 months)
    • Oxygen saturation <92%
    • Difficulty breathing (chest indrawing or nasal flaring)
    • Refusal to breastfeed or of infant formula or food for >24 hours
    • Repetitive or recurrent vomiting with no obvious other cause (>3 times in past 24 hours)
    • Persistent crying not relieved by soothing or feeding with no obvious other cause
    • Hoarse voice/cry or loss of voice
    • Nystagmus or other unusual eye movements
    • Muscle twitching
    • Loss of consciousness
    • Convulsion
    • Opisthotonos/abnormal posturing
    • Acute/flaccid paralysis

Exclusion Criteria:

  • Infants and young children who do not meet any of the TDD-like signs and symptoms will not be eligible for study participation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Other

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Thiamine responsive disorder (TRD)
Time Frame: From hospital admission to hospital discharge
Presenting signs and symptoms compatible with the thiamine responsive disorders (TRD) case definition and physician diagnosis of beriberi
From hospital admission to hospital discharge

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Risk factors for TDD/TRD
Time Frame: Baseline
Risk factors related to TDD, TRD and physician diagnosed beriberi
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 15, 2022

Primary Completion (Actual)

August 26, 2022

Study Completion (Actual)

August 26, 2022

Study Registration Dates

First Submitted

May 16, 2022

First Submitted That Met QC Criteria

May 23, 2022

First Posted (Actual)

May 25, 2022

Study Record Updates

Last Update Posted (Actual)

April 23, 2025

Last Update Submitted That Met QC Criteria

April 21, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The complete de-identified dataset will be made publicly available.

IPD Sharing Time Frame

Within 2 years of completion of the data collection

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Thiamine Deficiency

Clinical Trials on Standard of care

Subscribe